Shikonin Inhibites Migration and Invasion of Thyroid Cancer Cells by Downregulating DNMT1

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2018 Feb 2

PMID 29389913

Citations 19

Authors

Yue Zhang

Bin Sun

Zhi Huang

Dai-Wei Zhao

Qingfan Zeng

Affiliations

Soon will be listed here.

Abstract

BACKGROUND Shikonin is a component of Chinese herbal medicine. The aim of this study was to investigate the effects of shikonin on cell migration of papillary thyroid cancer cells of the TPC-1 cell line in vitro and expression levels of the phosphate and tensin homolog deleted on chromosome 10 (PTEN) and DNA methyltransferase 1 (DNMT1) genes. MATERIAL AND METHODS The Cell Counting Kit-8 (CCK-8) assay was performed to evaluate the proliferation of TPC-1 papillary thyroid cancer cells, and the normal thyroid cells, HTori-3, in vitro. A transwell motility assay was used to analyze the migration of TPC-1 cells. Western blot was performed to determine the expression levels of PTEN and DNMT1 genes. A methylation-specific polymerase chain reaction (PCR) (MSP) assay was used to evaluate the methylation of PTEN. RESULTS Following treatment with shikonin, the cell survival rate of TPC-1 cells decreased in a dose-dependent manner; the inhibitory effects on HTori-3 cells were less marked. Shikonin inhibited TPC-1 cell migration and invasion in a dose-dependent manner. The methylation of PTEN was suppressed by shikonin, which also reduced the expression of DNMT1 in a dose-dependent manner, and increased the expression of PTEN. Overexpression of DNMT1 promoted the migration of TPC-1 cells and the methylation of PTEN. Levels of protein expression of PTEN in TPC-1 cells treated with shikonin decreased, and were increased by DNMT1 knockdown. CONCLUSIONS Shikonin suppressed the expression of DNMT1, reduced PTEN gene methylation, and increased PTEN protein expression, leading to the inhibition of TPC-1 cell migration.

Citing Articles

Shikonin inhibits the growth of anaplastic thyroid carcinoma cells by promoting ferroptosis and inhibiting glycolysis.

Yang C, Yang L, Li D, Tan J, Jia Q, Sun H Heliyon. 2025; 10(14):e34291.

PMID: 39816344 PMC: 11734080. DOI: 10.1016/j.heliyon.2024.e34291.

METTL16 inhibits papillary thyroid cancer tumorigenicity through mA/YTHDC2/SCD1-regulated lipid metabolism.

Li Q, Wang Y, Meng X, Wang W, Duan F, Chen S Cell Mol Life Sci. 2024; 81(1):81.

PMID: 38334797 PMC: 10857971. DOI: 10.1007/s00018-024-05146-x.

DNMT1/DNMT3a-mediated promoter hypermethylation and transcription activation of ICAM5 augments thyroid carcinoma progression.

Li Z, Ying Y, Zeng X, Liu J, Xie Y, Deng Z Funct Integr Genomics. 2024; 24(1):12.

PMID: 38228798 DOI: 10.1007/s10142-024-01293-3.

Shikonin Induces ROS-Dependent Apoptosis Via Mitochondria Depolarization and ER Stress in Adult T Cell Leukemia/Lymphoma.

Boonnate P, Kariya R, Okada S Antioxidants (Basel). 2023; 12(4).

PMID: 37107239 PMC: 10135058. DOI: 10.3390/antiox12040864.

Developing an m5C regulator-mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer.

Zhang R, Gan W, Zong J, Hou Y, Zhou M, Yan Z Front Immunol. 2023; 14:1054700.

PMID: 36911744 PMC: 9992543. DOI: 10.3389/fimmu.2023.1054700.

References

Dirican E, Akkiprik M . Phosphatidylinositol 3-kinase regulatory subunit 1 and phosphatase and tensin homolog as therapeutic targets in breast cancer. Tumour Biol. 2017; 39(3):1010428317695529. DOI: 10.1177/1010428317695529. View

Nigorikawa K, Yoshikawa K, Sasaki T, Iida E, Tsukamoto M, Murakami H . A naphthoquinone derivative, shikonin, has insulin-like actions by inhibiting both phosphatase and tensin homolog deleted on chromosome 10 and tyrosine phosphatases. Mol Pharmacol. 2006; 70(3):1143-9. DOI: 10.1124/mol.106.025809. View

Goyal N, Setabutr D, Abdulghani J, Goldenberg D . Molecular and genetic markers of follicular-cell thyroid cancer: etiology and diagnostic and therapeutic opportunities. Adv Exp Med Biol. 2013; 779:309-26. DOI: 10.1007/978-1-4614-6176-0_14. View

Yin S, Efferth T, Jian F, Chen Y, Liu C, Wang A . Immunogenicity of mammary tumor cells can be induced by shikonin via direct binding-interference with hnRNPA1. Oncotarget. 2016; 7(28):43629-43653. PMC: 5190049. DOI: 10.18632/oncotarget.9660. View

Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R . Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013; 2013:965212. PMC: 3664492. DOI: 10.1155/2013/965212. View

Han W, Xie J, Fang Y, Wang Z, Pan H . Nec-1 enhances shikonin-induced apoptosis in leukemia cells by inhibition of RIP-1 and ERK1/2. Int J Mol Sci. 2012; 13(6):7212-7225. PMC: 3397521. DOI: 10.3390/ijms13067212. View

Dudek H, Datta S, Franke T, Birnbaum M, Yao R, Cooper G . Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 1997; 275(5300):661-5. DOI: 10.1126/science.275.5300.661. View

Fan Y, Jin S, He J, Shao Z, Yan J, Feng T . Effect of β,β-dimethylacrylshikonin on inhibition of human colorectal cancer cell growth in vitro and in vivo. Int J Mol Sci. 2012; 13(7):9184-9193. PMC: 3430290. DOI: 10.3390/ijms13079184. View

Esteller M, Silva J, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E . Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000; 92(7):564-9. DOI: 10.1093/jnci/92.7.564. View

10.

Curtin J, Fridlyand J, Kageshita T, Patel H, Busam K, Kutzner H . Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353(20):2135-47. DOI: 10.1056/NEJMoa050092. View

11.

Simpson L, Parsons R . PTEN: life as a tumor suppressor. Exp Cell Res. 2001; 264(1):29-41. DOI: 10.1006/excr.2000.5130. View

12.

Montiel-Duarte C, Cordeu L, Agirre X, Roman-Gomez J, Jimenez-Velasco A, Jose-Eneriz E . Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Leuk Res. 2007; 32(5):709-16. DOI: 10.1016/j.leukres.2007.09.005. View

13.

Myers M, Pass I, Batty I, van der Kaay J, Stolarov J, Hemmings B . The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A. 1998; 95(23):13513-8. PMC: 24850. DOI: 10.1073/pnas.95.23.13513. View

14.

Liu L, Li Y, Liu S, Duan Q, Chen L, Wu T . Downregulation of miR-193a-3p inhibits cell growth and migration in renal cell carcinoma by targeting PTEN. Tumour Biol. 2017; 39(6):1010428317711951. DOI: 10.1177/1010428317711951. View

15.

Sun H, Ma H, Wang J, Xia L, Zhu G, Wang Z . Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non-small-cell lung cancer. Tumour Biol. 2017; 39(7):1010428317709639. DOI: 10.1177/1010428317709639. View

16.

Bian E, Huang C, Ma T, Tao H, Zhang H, Cheng C . DNMT1-mediated PTEN hypermethylation confers hepatic stellate cell activation and liver fibrogenesis in rats. Toxicol Appl Pharmacol. 2012; 264(1):13-22. DOI: 10.1016/j.taap.2012.06.022. View

17.

Whang Y, Wu X, Suzuki H, Reiter R, Tran C, Vessella R . Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A. 1998; 95(9):5246-50. PMC: 20246. DOI: 10.1073/pnas.95.9.5246. View

18.

Brito J, Davies L . Is there really an increased incidence of thyroid cancer?. Curr Opin Endocrinol Diabetes Obes. 2014; 21(5):405-8. DOI: 10.1097/MED.0000000000000094. View

19.

Mao X, Yu C, Li W, Li W . Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell Res. 2008; 18(8):879-88. DOI: 10.1038/cr.2008.86. View

20.

Ng E, Shin V, Leung C, Chan V, Law F, Siu M . Elevation of methylated DNA in KILLIN/PTEN in the plasma of patients with thyroid and/or breast cancer. Onco Targets Ther. 2014; 7:2085-92. PMC: 4234161. DOI: 10.2147/OTT.S53597. View